Medicare AdvantageCoverageMedium impact
MA08.082o, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated coverage and medical necessity criteria for several colony-stimulating factor drugs including Ryzneuta, Rolvedon, Neulasta and related biosimilars. This affects both coverage determination and reimbursement positions for these oncology support medications.
Action Required
Before January 1, 2026: Billing team must review updated medical necessity criteria for efbemalenograstim alfa-vuxw (Ryzneuta), eflapegrastim-xnst (Rolvedon), pegfilgrastim (Neulasta) and related biosimilars. Update prior authorization processes and documentation requirements in billing system. Oncology providers should review new coverage criteria to ensure compliance with Medicare Advantage plans.